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Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly 
and can cause irreversible blindness and aortitis. Varicella zoster (VZ), which is potentially 
preventable by vaccination, has been proposed as a possible immune trigger for GCA, but this 
is controversial. The incidence of GCA varies widely by country. If VZ virus contributes to the 
immunopathogenesis of GCA we hypothesized that nations with increased incidence of GCA 
would also have increased incidence of herpes zoster (HZ). We conducted an ecologic analysis 
to determine the relationship between the incidence of HZ and GCA in different countries.
Methods: A literature search for the incidence rates (IRs) of GCA and HZ from different 
countries was conducted. Correlation and linear regression was performed comparing the disease 
IR of each country for subjects 50 years of age or older.
Results: We found the IR for GCA and HZ from 14 countries. Comparing the IRs for GCA 
and HZ in 50-year-olds, the Pearson product-moment correlation (r) was -0.51, with linear 
regression coefficient (β) -2.92 (95% CI -5.41, -0.43; p=0.025) using robust standard errors. 
Comparing the IRs for GCA and HZ in 70-year-olds, r was -0.40, with β -1.78, which was 
not statistically significant (95% CI -4.10, 0.53; p=0.12).
Conclusion: Although this geo-epidemiologic study has potential for aggregation and selec-
tion biases, there was no positive biologic gradient between the incidence of clinically evident 
HZ and GCA.
Keywords: epidemiology, shingles, temporal arteritis, immunopathogenesis
Introduction
Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly and 
can cause irreversible blindness, myocardial infarction, aortic aneurysm, stroke and 
rarely death.1 The incidence of GCA is projected to increase as our population ages, 
with predicted cost of $76 billion in the United States alone, by the year 2050.2
Gilden et al and Nagel et al found varicella zoster virus (VZV) in the temporal 
arteries of 73% of patients with biopsy-proven GCA and propose VZV as a possible 
trigger in the immunopathogenesis of GCA.3,4 Although this potential role of VZV 
in the development of GCA has not been substantiated by other investigators, and 
remains controversial, Gilden suggested adjunctive antivirals be considered in the 
treatment of GCA.5
The incidence rate (IR) of GCA varies widely by country, being the highest in 
northern Europe and lowest in Asia.2,6 We hypothesized that if VZV contributed to 
GCA, the GCA IRs per 100,000 subjects, 50 years of age or older (IR
GCA
) per country 
should correlate with the local herpes zoster IRs (IR
HZ
). To test this hypothesis, we 
performed a regression analysis using the published IR
GCA
 and IR
HZ
 from different 
countries.
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Methods
The IR
GCA
 was searched for on PubMed, Embase, and Google 
Scholar from inception to July 1, 2017 using the search 
terms: incidence, epidemiology, country, temporal arteritis 
and GCA. The same search was repeated using herpes zoster 
and shingles in place of the arteritis terms.
The country specific IRs for subjects 50 years of age and 
older were recorded per 100,000 population for GCA, and per 
1,000 person-years for HZ. If IRs were provided for multiple 
years, the results were averaged (Table 1).
The IR
GCA
 in Japan was calculated using Koboyashi’s 
reported prevalence rate of 1.47 per 100,000 in subjects aged 
50 years or older, with average age of onset of 71.5 years.7 
Lifespan is thought not to be affected by GCA unless the 
patient has aortic aneurysm or dissection.8 The average life 
expectancy in Japan is 83.3 years.9 As GCA is a rare disease 
and recurrent, the IR was estimated as the prevalence rate/
duration of disease =1.3 per million subjects 50 years or older.
Since the peak onset of GCA is in the 8th decade,10 we 
also examined the IR of HZ in 70 year-olds. If the age 
brackets straddled our chosen age cut-offs, the IR values 
from the two adjacent brackets were averaged.
Only countries/regions that had IRs available for both 
GCA and HZ were used for analysis. Paired t-test was 
used to examine the time difference in year of publication 
between the GCA and HZ studies for each country. There was 
inadequate information in the GCA articles to consistently 
calculate the within-study standard errors needed for meta-
regression. Pearson product-moment correlation coefficients, 
and linear regression with and without robust standard errors 
was performed. White’s test was used to test for heterosce-
dasticity. All statistical tests were conducted with Stata 14.2 
(StataCorp LP, College Station, TX, USA), and a two-sided 
p<0.05 was considered statistically significant.
Results
The IRs for both GCA and HZ were available for 14 countries 
(Table 1), and plotted on Figure 1. With the exception of 
Olmsted County and the United Kingdom, the availability 
of IR
GCA
 and IR
HZ
 from the same time frame and correspond-
ing geographic region was limited. Eight of the 14 countries 
(57%) in Table 1 were overlapping in the time frame of the 
corresponding GCA and HZ studies. On paired t-test, the 
GCA studies were published on average 4.5 years before 
the HZ studies (p=0.09). A published IR
GCA
 for Iceland was 
available. The IR
HZ
 for Iceland was only available for the 
60-year age group only (4.7 per 1,000), but not the 50-year-
old or 70-year-old age groups, and as such was not used.
Pearson product-moment correlation coefficient (r) com-
paring IR
GCA
 with: IR
HZ
 in 50 year-olds was -0.51 (p=0.07), 
and IR
HZ
 in 70-year-olds was -0.40 (p=0.16). Linear regres-
sion with robust standard errors showed a regression coef-
ficient (β) -2.92 (95% CI -5.41, -0.43; p=0.025) between 
the IR
GCA
 $50-year-olds, and the IR
HZ
 in 50-year-olds. 
For the IR
HZ
 in 70-year-olds, no statistically significant 
linear dependence of the mean IR
GCA
 on IR
HZ
 was detected 
(β=-1.78, 95% CI -4.10, 0.53; p=0.12). White’s test did not 
suggest heteroscedasticity (Table 2).
Table 1 incidence rates of giant cell arteritis and herpes zoster per country
Country GCA study: year published 
(study period)/region
IRGCA HZ study: year/region IRHZ50 IRHZ70 Time 
overlap
Norway, B+C37 2014 (2006–2012)/south 21 2016 (2008–2012)/National38 2.8 7.0 yes
Finland, B+C39 1992 (1984–1988)/West Nyland 26.2 2010 (2000–2006)/tuusula, Kangasala, salo40 2.5 6.5 No
sweden, B41 2015 (1997–2010)/skane 14.1 2013 (2006–2010)/National42 2.5 8.0 yes
United Kingdom, B+C43 2006 (1990–2001)/National 22 2003 (1991–2000)/National44 4.0 9.3 yes
UsA, C45 2015 (2000–2009)/Olmsted Cty 19.8 2016 (1945–2007)/Olmsted City46 4.5 8.4 yes
spain, B47 2007 (1981–2005)/Lugo 10.13 2013 (2007–2010)/Valencian Community48 4.8 9.8 No
New Zealand, B49 2011 (1996–2005)/Otago 12.73 2014 (2009–2013)/Lower Hutt50 6.1 7.3 No
israel, B+C51 2007 (1980–2004)/Jerusalem 11.3 2013 (2006–2010)/tel Aviv52 5.8 11.8 No
Canada, B53 2007 (1998–2003)/saskatoon 9.4 2011 (1992–2010)/Ontario54 3.7 7.4 yes
France, B+C55 1982 (1970–1979)/Loire-Atlantique 9.4 2010 (2005–2007)/National56 4.2 8.7 No
italy, B+C57 2017 (1986–2012)/Reggio emilia 5.8 2010 (2003–2005)/National58 3.6 7.7 yes
Australia, B59 2013 (1992–2011)/Adelaide 3.2 2008 (1998–2006)/National60 6.5 11.5 yes
Germany, C61 2005 (1998–2002)/schlewig-Holstein 3.3 2011 (2007–2008)/National62 6.2 11.3 No
Japan, Cal7 2003 (1998)/National 0.13 2009 (1997–2006)/Miyazaki63 3.9 7.4 yes
Notes: B, biopsy proven; C, clinical criteria for diagnosis; Cal, calculated from published prevalence rate; time overlap, the incidence rates for GCA and HZ were from the 
same time period.
Abbreviations: GCA, giant cell arteritis; iR, incidence rate; iRGCA, giant cell arteritis incidence rates per 100,000 subjects, 50 years of age or older; HZ, herpes zoster; 
iRHZ50, herpes zoster incidence rates in 50-year-old subjects per 1,000 person years; iRHZ70, herpes zoster incidence rates in 70-year-old subjects per 1,000 person years.
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This ecologic study does not support a positive biologic 
gradient between the IR
HZ
 and IR
GCA
. Subgroup regression 
analyses of the per country IR
GCA
 and IR
HZ
, with and without 
overlapping timeframes were not statistically significant and 
did not show a positive regression coefficient.
Discussion
Infections can predispose to systemic vasculitis by mecha-
nisms such as molecular mimicry, epitope spreading, immune 
response to subdominant epitopes normally hidden from 
T-cell recognition, or bystander activation.11 If there is a 
causal relationship between HZ and GCA it is important 
to define since HZ can be potentially prevented with the 
shingles vaccine, and because the treatment of GCA might 
benefit from adjunctive antivirals.
VZV and GCA have some overlapping features. Dendritic 
cells are thought to play a central role in VZV infection and 
the immunopathogenesis of GCA.12–14 HZ ophthalmicus or 
multifocal VZV vasculopathy with temporal artery infec-
tion may mimic the presentation of GCA. Varicella zoster 
vasculopathy and GCA can both cause optic neuropathy, 
cranial nerve palsy, and stroke.
Temporal artery biopsy studies have shown conflicting 
results on the association of VZV and GCA. Gilden et al and 
Nagel et al suggested that VZV triggers the immunopathology 
of GCA, and found increase of 74% VZV in temporal artery 
biopsy specimens from patients with GCA.3–5,15 However, 
with the exception of Mitchell and Font,16 other investigators 
have not found substantial VZV in the arterial specimens 
of biopsy-proven GCA or clinically diagnosed GCA.17–22 
False positive immunohistochemistry from antibody cross-
reactivity to shared epitopes between VZV proteins and 
arterial smooth muscle elements suggest caution when inter-
preting pathology findings.23 Gilden and Nagel acknowledge 
Table 2 Correlation and linear regression of the incidence rates of giant cell arteritis versus herpes zoster
Zoster incidence rate 
age groups
Number of 
countries
Correlation
coefficient
Regression 
coefficient
p-value, R2 p-value with 
robust SE
p-value for 
white’s test
50-year-olds, all countries 14 -0.51 -2.92 p=0.07, R2=0.26 p=0.025 p=0.28
70-year-olds, all countries 14 -0.40 -1.78 p=0.16, R2=0.16 p=0.12 p=0.42
50-year-olds, time overlap 8 -0.38 -2.66 p=0.35, R2=0.14 p=0.06 p=0.12
70-year-olds, time overlap 8 -0.15 -0.88 p=0.72, R2=0.02 p=0.69 p=0.88
50-year-olds, no overlap 6 -0.80 -4.24 p=0.06, R2=0.63 p=0.05 p=0.93
70-year-olds, no overlap 6 -0.74 -2.63 p=0.09, R2=0.54 p=0.14 p=0.09
Notes: Correlation coefficient, Pearson product-moment correlation coefficient (r); regression coefficient, linear regression coefficient; time overlap, the incidence rates for 
GCA and HZ were from the same time period; no overlap, the incidence rates for GCA and HZ were from different time periods.
Abbreviations: GCA, giant cell arteritis; HZ, herpes zoster; se, standard error.
Figure 1 incidence of giant cell arteritis versus incidence of herpes zoster per country.
Notes: each dot represents a country’s intersecting incidence rates for giant cell arteritis in subjects 50 years or older, and herpes zoster in 50 year-old subjects. the negative 
sloping red line is the line of best linear fit using the least squares method.
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that “the presence of VZV in about 20% of temporal artery 
biopsies from non-GCA post-mortem controls also suggests 
that VZV alone is not sufficient to produce disease”.5
A population-based cohort study did not find an increased 
risk of HZ in patients with GCA compared to non-GCA 
subjects, even during the first 6 months after glucocorticoid 
initiation, when patients are on the highest doses.24 A large 
nested case control study determined that HZ had a mod-
est incidence rate ratio of 1.17 in association with incident 
GCA.25 A review of two large administrative databases found 
a two-fold increased risk of GCA with complicated HZ.26
Our ecologic study did not show a positive biologic gra-
dient between the IR
HZ
 and IR
GCA
. Limitations of this study 
include possible ecologic fallacy, time, location and/or selec-
tion biases, the limited availability of IR
GCA
 and IR
HZ
, and 
variable trends in IR. By and large the IR
HZ
 are increasing.27 
Zoster sine herpete and asymptomatic VZV infection may 
have affected our analysis. The IR
GCA
 may be increasing,2 
decreasing,6 or cyclical.28 Furthermore, the IR
GCA
 are higher 
when cases of clinically diagnosed GCA are included with 
biopsy-proven GCA. It is unlikely that the IR
HZ
 in Table 1 were 
significantly affected by zoster vaccination. The Oka/Merck 
zoster vaccine decreases the risk of shingles by only 51%,29 and 
was approved for use in the United States and European Union 
in 2006,30,31 and in Canada in 2008.32 The Olmsted county HZ 
study published in 2016 reviewed two sets of patients, the latest 
of which were from 1980 to 2007. In the United States a 5% 
random sample of Medicare seniors were first offered zoster 
vaccine in 2007, and uptake was low at 3.9%.33 The first two 
European countries to recommend nation-wide zoster vaccina-
tion for seniors 65 to 74 years of age were the United Kingdom 
and France in 2013.34 The Australian and Ontario, Canada 
immunization programs for seniors began in 2016.35,36
Conclusion
The discordant IRs for HZ and GCA question the biologic 
plausibility of clinically overt HZ as the sole immunopatho-
genic trigger for GCA. Geo-epidemiology may help elucidate 
the relationship between VZV and GCA, but more widely 
available, accurate and updated IRs from different countries 
are required.
Disclosure
The authors report no conflicts of interest in this work.
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